Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs.
Gutierrez-Ardila MV, Reyes J, Madariaga H, Otero W, Guzman R, Izquierdo J, Abello M, Velez P, Castillo D, Ponce de Leon D, Lukic T, Amador L. Gutierrez-Ardila MV, et al. Among authors: velez p. Expert Rev Pharmacoecon Outcomes Res. 2022 Jul;22(5):787-794. doi: 10.1080/14737167.2022.2047935. Epub 2022 Mar 16. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 35249439
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC, Cardiel MH, Citera G, Goecke A, Jaller JJ, Lomonte ABV, Miranda P, Velez P, Xibillé D, Kwok K, Rojo R, García EG. Radominski SC, et al. Among authors: velez p. Reumatol Clin. 2017 Jul-Aug;13(4):201-209. doi: 10.1016/j.reuma.2016.04.010. Epub 2016 Jun 15. Reumatol Clin. 2017. PMID: 27317492 Free article. English, Spanish.
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC. Marcé S, et al. Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22. Med Clin (Barc). 2013. PMID: 23433665
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R, Rumba-Rozenfelde I, Breda L, Dolezalova P, Job-Deslandre C, Wulffraat N, Alvarez D, Zang C, Wajdula J, Woodworth D, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Horneff G, et al. Ann Rheum Dis. 2014 Jun;73(6):1114-22. doi: 10.1136/annrheumdis-2012-203046. Epub 2013 May 21. Ann Rheum Dis. 2014. PMID: 23696632 Free PMC article. Clinical Trial.
Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M, Ribera JM, García O, Cabezón M, Vélez P, Marcé S, Xicoy B, Fernández C, Buch J, Cortes M, Plensa E, Gallardo D, Boqué C, Feliu E, Zamora L. Sorigué M, et al. Among authors: velez p. Eur J Haematol. 2016 Oct;97(4):331-5. doi: 10.1111/ejh.12731. Epub 2016 Jan 19. Eur J Haematol. 2016. PMID: 26714837
Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Marcé S, Xicoy B, García O, Cabezón M, Estrada N, Vélez P, Boqué C, Sagüés M, Angona A, Teruel-Montoya R, Ferrer-Marín F, Amat P, Hernández-Boluda JC, Ibarra MM, Anguita E, Cortés M, Fernández-Ruiz A, Fontanals S, Zamora L, On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc. Marcé S, et al. Among authors: velez p. J Clin Med. 2021 Jul 16;10(14):3146. doi: 10.3390/jcm10143146. J Clin Med. 2021. PMID: 34300312 Free PMC article.
Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.
Zamora L, Xicoy B, Cabezón M, Fernandez C, Marcé S, Velez P, Xandri M, Gallardo D, Millá F, Feliu E, Boqué C. Zamora L, et al. Among authors: velez p. Leuk Lymphoma. 2015;56(10):2973-4. doi: 10.3109/10428194.2015.1015124. Epub 2015 Mar 11. Leuk Lymphoma. 2015. PMID: 25686645 No abstract available.
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, Vega MM, Alvarez-Larrán A, Salamanca A, García-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Pérez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jiménez-Velasco A, Lakhwani S, Casado LF, Rosell A, Escola A, Fernández MJ, Garcia-Hernandez C, Cervero C, Mora E, Sagüés M, Suarez-Varela S, Vélez P, Carrascosa Mastell P, Bitaube RF, Serrano L, Cortes M, Vera Goñi JA, Steegmann JL, de Soria VGG, Alonso-Dominguez JM, Araujo MC, Coll AP, Hernandez-Boluda JC, García-Gutiérrez V. Luna A, et al. Among authors: velez p. Ann Hematol. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. Epub 2022 Aug 23. Ann Hematol. 2022. PMID: 35997804 Free PMC article.
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, Giraldo P, Angona A, Alvarez-Larrán A, Sanchez-Guijo F, Ramírez MJ, Mora E, Vélez P, Rosell A, Colorado Araujo M, Cuevas B, Sagüés M, Cortes M, Encinas MP, Casado Montero LF, Moreno Vega M, Serrano L, Gomez V, Garcia-Hernandez C, Lakhwani S, Paz Coll A, de Paz R, Suarez-Varela S, Fernandez-Ruiz A, Perez Lopez R, Ortiz-Fernández A, Jiménez-Velasco A, Steegmann-Olmedillas JL, Hernández-Boluda JC. Garcia-Gutiérrez V, et al. Among authors: velez p. Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8. Blood Cancer J. 2021. PMID: 33563899 Free PMC article. No abstract available.
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.
Pastor-Galán I, Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F; en representación del Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Pastor-Galán I, et al. Among authors: velez p. Med Clin (Barc). 2020 Aug 28;155(4):152-158. doi: 10.1016/j.medcli.2019.11.007. Epub 2020 Jan 21. Med Clin (Barc). 2020. PMID: 31980217 English, Spanish.
122 results